M. M. Ozbalak Et Al. , "Long-term results of brentuximab vedotin in relapsed and refractory Hodgkin lymphoma: multi-center real-life experience.," Annals of hematology , vol.99, no.2, pp.301-307, 2020
Ozbalak, M. M. Et Al. 2020. Long-term results of brentuximab vedotin in relapsed and refractory Hodgkin lymphoma: multi-center real-life experience.. Annals of hematology , vol.99, no.2 , 301-307.
Ozbalak, M. M., SALİHOĞLU, A., Soysal, T., Karadogan, I., PAYDAŞ, S., Ozdemir, E., ... Yildiz, B.(2020). Long-term results of brentuximab vedotin in relapsed and refractory Hodgkin lymphoma: multi-center real-life experience.. Annals of hematology , vol.99, no.2, 301-307.
Ozbalak, Mustafa Et Al. "Long-term results of brentuximab vedotin in relapsed and refractory Hodgkin lymphoma: multi-center real-life experience.," Annals of hematology , vol.99, no.2, 301-307, 2020
Ozbalak, Mustafa M. Et Al. "Long-term results of brentuximab vedotin in relapsed and refractory Hodgkin lymphoma: multi-center real-life experience.." Annals of hematology , vol.99, no.2, pp.301-307, 2020
Ozbalak, M. M. Et Al. (2020) . "Long-term results of brentuximab vedotin in relapsed and refractory Hodgkin lymphoma: multi-center real-life experience.." Annals of hematology , vol.99, no.2, pp.301-307.
@article{article, author={Mustafa Murat ÖZBALAK Et Al. }, title={Long-term results of brentuximab vedotin in relapsed and refractory Hodgkin lymphoma: multi-center real-life experience.}, journal={Annals of hematology}, year=2020, pages={301-307} }